Phase I/II trial of capecitabine plus irinotecan for metastatic breast cancer patient who pretreated with anthracycline and taxane agents
Not Applicable
- Conditions
- metastatic breast cancer
- Registration Number
- JPRN-UMIN000001531
- Lead Sponsor
- ational cancer center hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patient have no indication of chemotherapy 2)patient who have priortreated with capecitabine or irinotecan
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method